Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning

Citations Over TimeTop 1% of 2020 papers

Abstract

There have been more than 2.2 million confirmed cases and over 120 000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there is currently a lack of proven effective medications against COVID-19. Drug repurposing offers a promising route for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep-learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, proteins/genes, pathways, and expression from a large scientific corpus of 24 million PubMed publications. Using Amazon's AWS computing resources and a network-based, deep-learning framework, we identified 41 repurposable drugs (including dexamethasone, indomethacin, niclosamide, and toremifene) whose therapeutic associations with COVID-19 were validated by transcriptomic and proteomics data in SARS-CoV-2-infected human cells and data from ongoing clinical trials. Whereas this study by no means recommends specific drugs, it demonstrates a powerful deep-learning methodology to prioritize existing drugs for further investigation, which holds the potential to accelerate therapeutic development for COVID-19.

Related Papers

• → The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions(2018)113 cited
• → A data-driven methodology towards evaluating the potential of drug repurposing hypotheses(2021)29 cited
• → Treatment Repurposing using Literature-related Discovery(2019)4 cited
• → Drug Repurposing and Multi-Target Therapies(2018)2 cited
• → Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.(2021)